Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.

Harper DM, Nieminen P, Donders G, Einstein MH, Garcia F, Huh WK, Stoler MH, Glavini K, Attley G, Limacher JM, Bastien B, Calleja E.

Gynecol Oncol. 2019 Jun;153(3):521-529. doi: 10.1016/j.ygyno.2019.03.250. Epub 2019 Apr 4.

2.

Optimizing Women's Health in Primary Care.

Harper DM, Godfrey EM.

Prim Care. 2018 Dec;45(4):xiii-xiv. doi: 10.1016/j.pop.2018.10.001. No abstract available.

PMID:
30401355
3.

Will increasing dosing intervals decrease the loss of anti-HPV seropositivity over time?

DeMars LR, Meza R, Harper DM.

Vaccine. 2018 Aug 9;36(33):4966. doi: 10.1016/j.vaccine.2018.03.090. No abstract available.

PMID:
30033074
4.

Influencers and preference predictors of HPV vaccine uptake among US male and female young adult college students.

LaJoie AS, Kerr JC, Clover RD, Harper DM.

Papillomavirus Res. 2018 Jun;5:114-121. doi: 10.1016/j.pvr.2018.03.007. Epub 2018 Mar 23.

5.

Hypothesis generating data - HPV vaccines - A decade in review.

Harper DM, DeMars LR.

Gynecol Oncol Rep. 2017 Nov 24;22:115-116. doi: 10.1016/j.gore.2017.11.008. eCollection 2017 Nov. No abstract available.

6.

Corrigendum to "HPV vaccines-A review of the first decade" [Gynecol. Oncol. 146 (2017) 196-204].

Harper DM, DeMars LR.

Gynecol Oncol. 2017 Nov;147(2):489. doi: 10.1016/j.ygyno.2017.08.019. Epub 2017 Aug 24. No abstract available.

7.

HPV vaccines - A review of the first decade.

Harper DM, DeMars LR.

Gynecol Oncol. 2017 Jul;146(1):196-204. doi: 10.1016/j.ygyno.2017.04.004. Epub 2017 Apr 22. Review. Erratum in: Gynecol Oncol. 2017 Nov;147(2):489.

8.

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.

Tota JE, Struyf F, Merikukka M, Gonzalez P, Kreimer AR, Bi D, Castellsagué X, de Carvalho NS, Garland SM, Harper DM, Karkada N, Peters K, Pope WAJ, Porras C, Quint W, Rodriguez AC, Schiffman M, Schussler J, Skinner SR, Teixeira JC, Wheeler CM, Herrero R, Hildesheim A, Lehtinen M; Costa Rica Vaccine Trial and the PATRICIA study groups.

J Natl Cancer Inst. 2017 Jan 28;109(7). doi: 10.1093/jnci/djw300. Print 2017 Jan.

9.

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial.

Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, de Borba PC, Teixeira JC, Blatter M, Moscicki AB, Harper DM, Romanowski B, Tyring SK, Ramjattan B, Schuind A, Dubin G, Franco EL; HPV-007 Study Group.

BMJ Open. 2016 Aug 26;6(8):e011371. doi: 10.1136/bmjopen-2016-011371. Erratum in: BMJ Open. 2016 Sep 02;6(9):e011371corr1.

10.

Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Harrison MS, Eckert LO, Cutland C, Gravett M, Harper DM, McClure EM, Nunes AP, Lazo S, Moore TM, Watson W, Kochhar S, Goldenberg RL; Brighton Collaboration Pathways to Preterm Birth Working Group. Electronic address: contact@brightoncollaboration.org.

Vaccine. 2016 Dec 1;34(49):6093-6101. doi: 10.1016/j.vaccine.2016.03.054. Epub 2016 Aug 1. No abstract available.

11.

Stillbirth: Case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data.

Tavares Da Silva F, Gonik B, McMillan M, Keech C, Dellicour S, Bhange S, Tila M, Harper DM, Woods C, Kawai AT, Kochhar S, Munoz FM; Brighton Collaboration Stillbirth Working Group.

Vaccine. 2016 Dec 1;34(49):6057-6068. doi: 10.1016/j.vaccine.2016.03.044. Epub 2016 Jul 16. No abstract available.

12.

Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.

US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FAR, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL.

JAMA. 2016 Jun 21;315(23):2564-2575. doi: 10.1001/jama.2016.5989. Erratum in: JAMA. 2016 Aug 2;316(5):545. Erratum in: JAMA. 2017 Jun 6;317(21):2239.

PMID:
27304597
13.

Screening for Syphilis Infection in Nonpregnant Adults and Adolescents: US Preventive Services Task Force Recommendation Statement.

US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, García FA, Gillman MW, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Pignone MP.

JAMA. 2016 Jun 7;315(21):2321-7. doi: 10.1001/jama.2016.5824. Review.

PMID:
27272583
14.

Associations between prior HPV4 vaccine doses and cervical cancer screening participation.

Boone SD, Pinkston CM, Baumgartner KB, Baumgartner RN, Harper SM, Bonham AJ, Paynter CA, Harper DM.

Cancer Epidemiol. 2016 Jun;42:108-14. doi: 10.1016/j.canep.2016.04.003. Epub 2016 Apr 18.

PMID:
27100836
15.

Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Recommendation Statement.

US Preventive Services Task Force (USPSTF), Siu AL, Bibbins-Domingo K, Grossman DC, Davidson KW, Epling JW Jr, García FA, Gillman M, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Harper DM, Phillips WR, Phipps MG, Pignone MP.

JAMA. 2016 Apr 5;315(13):1372-7. doi: 10.1001/jama.2016.2638.

PMID:
27046365
16.

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.

Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, Romanowski B, Roteli-Martins C, Burlet N, Mihalyi A, Struyf F.

Expert Rev Vaccines. 2016;15(3):367-87. doi: 10.1586/14760584.2016.1124763. Review.

PMID:
26902666
17.

Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population.

Paynter CA, Van Treeck BJ, Verdenius I, Lau AW, Dhawan T, Lash KA, Bergamini EA, Ekekezie CN, Hilal AM, James KN, Alongi S, Harper SM, Bonham AJ, Baumgartner KB, Baumgartner RN, Harper DM.

Prev Med Rep. 2015 Jul 31;2:711-6. doi: 10.1016/j.pmedr.2015.07.011. eCollection 2015.

18.

Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.

Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L; VIVIANE Study Group.

Int J Cancer. 2016 May 15;138(10):2428-38. doi: 10.1002/ijc.29971.

19.

Incorporating Osteopathic Curriculum Into a Family Medicine Residency.

Hempstead LK, Harper DM.

Fam Med. 2015 Nov-Dec;47(10):794-8.

20.

No evidence in US of HPV16/18 cancer precursor reduction.

Pendleton ME, Ruffin MT 4th, Harper DM.

Vaccine. 2016 Jan 4;34(2):200. doi: 10.1016/j.vaccine.2015.07.047. Epub 2015 Jul 29. No abstract available.

PMID:
26232544
21.

Climate Change and European Water Bodies, a Review of Existing Gaps and Future Research Needs: Findings of the ClimateWater Project.

Garnier M, Harper DM, Blaskovicova L, Hancz G, Janauer GA, Jolánkai Z, Lanz E, Lo Porto A, Mándoki M, Pataki B, Rahuel JL, Robinson VJ, Stoate C, Tóth E, Jolánkai G.

Environ Manage. 2015 Aug;56(2):271-85. doi: 10.1007/s00267-015-0544-7. Epub 2015 Jun 16.

PMID:
26076892
22.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group.

Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.

23.

Spontaneous rupture of unscarred uterus in a primigravida with preterm prelabour rupture of membranes.

Mourad WS, Bersano DJ, Greenspan PB, Harper DM.

BMJ Case Rep. 2015 Jun 8;2015. pii: bcr2014207321. doi: 10.1136/bcr-2014-207321.

24.

ACP Journal Club: IIV3 reduced flu in HIV- pregnant women and infants, and in HIV+ pregnant women but not their infants.

Fernandez LM, Girdler RV, Wright RB, Harper DM.

Ann Intern Med. 2015 Feb 17;162(4):JC6. doi: 10.7326/ACPJC-2015-162-4-006. No abstract available.

PMID:
25686193
25.

Response to philanthropic support of HPV vaccination efforts.

Harper DM, Wall J, Verdenius I, Harris GD.

Prev Med. 2015 Jul;76:127-8. doi: 10.1016/j.ypmed.2014.12.042. Epub 2015 Feb 2. No abstract available.

PMID:
25657170
26.

Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.

Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow SN, Salmerón J, Lehtinen M, Del Rosario-Raymundo MR, Paavonen J, Teixeira JC, Germar MJ, Peters K, Skinner SR, Limson G, Castellsagué X, Poppe WA, Ramjattan B, Klein TD, Schwarz TF, Chatterjee A, Tjalma WA, Diaz-Mitoma F, Lewis DJ, Harper DM, Molijn A, van Doorn LJ, David MP, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Feb;22(2):235-44. doi: 10.1128/CVI.00457-14. Epub 2014 Dec 24.

27.

In a safety net population HPV4 vaccine adherence worsens as BMI increases.

Harper DM, Else BM, Bartley MJ, Arey AM, Barnett AL, Rosemergey BE, Paynter CA, Verdenius I, Harper SM, Harris GD, Groner JA, Malnar GJ, Wall J, Bonham AJ.

PLoS One. 2014 Jul 30;9(7):e103172. doi: 10.1371/journal.pone.0103172. eCollection 2014.

28.

Intent to participate in future cervical cancer screenings is lower when satisfaction with the decision to be vaccinated is neutral.

Alexander NM, Harper DM, Comes JC, Smith MS, Heutinck MA, Handley SM, Ahern DA.

PLoS One. 2014 Jun 10;9(6):e98665. doi: 10.1371/journal.pone.0098665. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e107790.

29.

Women have a preference for their male partner to be HPV vaccinated.

Harper DM, Alexander NM, Ahern DA, Comes JC, Smith MS, Heutinck MA, Handley SM.

PLoS One. 2014 May 14;9(5):e97119. doi: 10.1371/journal.pone.0097119. eCollection 2014.

30.

Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion rates.

Sandri KJ, Verdenius I, Bartley MJ, Else BM, Paynter CA, Rosemergey BE, Harris GD, Malnar GJ, Harper SM, Griffith RS, Bonham AJ, Harper DM.

PLoS One. 2014 May 9;9(5):e96277. doi: 10.1371/journal.pone.0096277. eCollection 2014.

31.

Decadal trends and common dynamics of the bio-optical and thermal characteristics of the African Great Lakes.

Loiselle S, Cózar A, Adgo E, Ballatore T, Chavula G, Descy JP, Harper DM, Kansiime F, Kimirei I, Langenberg V, Ma R, Sarmento H, Odada E.

PLoS One. 2014 Apr 3;9(4):e93656. doi: 10.1371/journal.pone.0093656. eCollection 2014.

32.

Primary strategies for HPV infection and cervical cancer prevention.

Harper DM, Demars LR.

Clin Obstet Gynecol. 2014 Jun;57(2):256-78. doi: 10.1097/GRF.0000000000000027. Review.

PMID:
24686336
33.

Quantifying the decisional satisfaction to accept or reject the Human Papillomavirus (HPV) vaccine: a preference for cervical cancer prevention.

Harper DM, Irons BB, Alexander NM, Comes JC, Smith MS, Heutinck MA, Handley SM, Ahern DA.

PLoS One. 2014 Feb 14;9(2):e88493. doi: 10.1371/journal.pone.0088493. eCollection 2014.

34.

Conclusions about the quadrivalent human papillomavirus vaccine efficacy based on alternate dosing schedules and less than three dose immunogenicity is inappropriate.

Harper DM.

J Infect Dis. 2014 Jul 15;210(2):330-1. doi: 10.1093/infdis/jiu072. Epub 2014 Feb 5. No abstract available.

PMID:
24501212
35.

The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series.

Harper DM, Verdenius I, Harris GD, Barnett AL, Rosemergey BE, Arey AM, Wall J, Malnar GJ.

Prev Med. 2014 Apr;61:20-5. doi: 10.1016/j.ypmed.2014.01.007. Epub 2014 Jan 15.

PMID:
24440159
36.

Positive high-risk HPV test with negative cytology--a conundrum and blessing of our latest technology.

Harper DM, Groner JA.

Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):10-1. doi: 10.1158/1055-9965.EPI-13-0708. No abstract available.

37.

Reduction in HPV prevalence--no evidence to support HPV vaccination reduces HPV prevalence.

Groner JA, Harris GD, Harper DM.

J Infect Dis. 2014 Apr 15;209(8):1302-4. doi: 10.1093/infdis/jit836. Epub 2013 Dec 23. No abstract available.

PMID:
24368836
38.

ACP Journal Club. Review: Combined oral contraceptives are associated with venous thrombosis.

Harper DM, Wilfling LE, Blanner CF.

Ann Intern Med. 2013 Dec 17;159(12):JC12. doi: 10.7326/0003-4819-159-12-201312170-02012. No abstract available.

PMID:
24343405
39.

Long-term follow-up of HPV16-positive women: persistence of the same genetic variant and low prevalence of variant co-infections.

Geraets DT, van Doorn LJ, Kleter B, Colau B, Harper DM, Quint WG.

PLoS One. 2013 Nov 11;8(11):e80382. doi: 10.1371/journal.pone.0080382. eCollection 2013.

40.

Quantifying clinical HPV4 dose inefficiencies in a safety net population.

Harper DM, Verdenius I, Ratnaraj F, Arey AM, Rosemergey B, Malnar GJ, Wall J.

PLoS One. 2013 Nov 6;8(11):e77961. doi: 10.1371/journal.pone.0077961. eCollection 2013.

41.

ACP Journal Club. Review: Yoga reduces low back pain and back-specific disability.

Harper DM.

Ann Intern Med. 2013 Oct 15;159(8):JC13. doi: 10.7326/0003-4819-159-8-201310150-02013. No abstract available.

PMID:
24126662
42.

Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.

Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsagué X, Poppe WA, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torné A, David MP, Struyf F, Lehtinen M, Dubin G.

J Infect Dis. 2013 Nov 1;208(9):1391-6. doi: 10.1093/infdis/jit360.

43.

Predictors of three dose on-time compliance with HPV4 vaccination in a disadvantaged, underserved, safety net population in the US Midwest.

Verdenius I, Harper DM, Harris GD, Griffith RS, Wall J, Hempstead LK, Malnar GJ, Bekkers RL.

PLoS One. 2013 Aug 8;8(8):e71295. doi: 10.1371/journal.pone.0071295. eCollection 2013.

44.

Sustainable utilization and conservation of plant biodiversity in montane ecosystems: the western Himalayas as a case study.

Khan SM, Page SE, Ahmad H, Harper DM.

Ann Bot. 2013 Aug;112(3):479-501. doi: 10.1093/aob/mct125. Epub 2013 Jul 3. Review.

45.

Speculation overinflates long-term efficacy of vaccine for anal dysplasia.

Talboy GE, Lankachandra K, Harper DM.

Lancet Oncol. 2013 Jun;14(7):e249-50. doi: 10.1016/S1470-2045(13)70171-2. No abstract available.

PMID:
23725702
47.

Cross protection against HPV might prevent type replacement.

Verdenius I, Groner JA, Harper DM.

Lancet Infect Dis. 2013 Mar;13(3):195. doi: 10.1016/S1473-3099(13)70024-0. No abstract available.

PMID:
23427887
48.

Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis.

Dillingh MR, van den Blink B, Moerland M, van Dongen MG, Levi M, Kleinjan A, Wijsenbeek MS, Lupher ML Jr, Harper DM, Getsy JA, Hoogsteden HC, Burggraaf J.

Pulm Pharmacol Ther. 2013 Dec;26(6):672-6. doi: 10.1016/j.pupt.2013.01.008. Epub 2013 Feb 4.

PMID:
23380438
49.

Medicinal flora and ethnoecological knowledge in the Naran Valley, Western Himalaya, Pakistan.

Khan SM, Page S, Ahmad H, Shaheen H, Ullah Z, Ahmad M, Harper DM.

J Ethnobiol Ethnomed. 2013 Jan 10;9:4. doi: 10.1186/1746-4269-9-4.

50.

Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.

Roset Bahmanyar E, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Skinner SR, Jaisamrarn U, Limson GA, Garland SM, Szarewski A, Romanowski B, Aoki F, Schwarz TF, Poppe WA, De Carvalho NS, Harper DM, Bosch FX, Raillard A, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Gynecol Oncol. 2012 Dec;127(3):440-50. doi: 10.1016/j.ygyno.2012.08.033. Epub 2012 Aug 30.

Supplemental Content

Loading ...
Support Center